Mismatched outcomes.

Busting wide open another large market share, abstract reporting of KEYNOTE-177 demonstrates blockbuster improvements in median progression free survival (PFS) from 8 months with standard chemo (even allowing the addition of bevacizumab or cetuximab per physician preference) to nearly 17 months with upfront pembro among 307 patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer. Put another (impressive) way, PFS at 2 years was improved from 19 → 48%. | Andre, ASCO 2020